Payment overview · 2025
General Payments
$1,429.17
47 reported records · 12 companies
Healthcare provider profile · identity verified
Huynh Tran, MD, DPD
Allopathic & Osteopathic Physicians|Internal Medicine · ROSEMEAD, CA · NPI 1649566571
Verified facts
What the public records show
CMS Open Payments records show Huynh Tran, MD, DPD received $1,429.17 in general payments during 2025 across 47 reported records.
AstraZeneca Pharmaceuticals LP accounted for 19.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $272.76 | 19.1% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $264.77 | 18.5% | 12 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $262.51 | 18.4% | 7 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $221.46 | 15.5% | 8 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $88.45 | 6.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $80.67 | 5.6% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $63.74 | 4.5% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $61.48 | 4.3% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $36.03 | 2.5% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $26.43 | 1.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $25.89 | 1.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.98 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,429.17 | 47 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $262.51 | 7 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $242.31 | 11 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $221.46 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $151.19 | 6 | 2025 |
Source payment records
|
|||||
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $121.57 | 1 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $80.67 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $63.74 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $61.48 | 1 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $38.49 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $36.03 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $26.43 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $25.89 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $24.98 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $24.98 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $22.46 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $22.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
87 | 55 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
84 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
87 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1906 | 454 |
| Amlodipine Besylate | Amlodipine Besylate | 1557 | 374 |
| Losartan Potassium | Losartan Potassium | 1337 | 338 |
| Gabapentin | Gabapentin | 1111 | 292 |
| Metformin Hcl | Metformin Hcl | 1076 | 258 |
| Atenolol | Atenolol | 557 | 121 |
| Alendronate Sodium | Alendronate Sodium | 531 | 136 |
| Fluocinonide | Fluocinonide | 524 | 156 |
| Tamsulosin Hcl | Tamsulosin Hcl | 507 | 135 |
| Omeprazole | Omeprazole | 472 | 141 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 463 | 169 |
| Azelastine Hcl | Azelastine Hcl | 435 | 126 |
| Famotidine | Famotidine | 386 | 111 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 379 | 92 |
| Diclofenac Sodium | Diclofenac Sodium | 365 | 134 |
| Simvastatin | Simvastatin | 351 | 85 |
| Celecoxib | Celecoxib | 304 | 89 |
| Ibuprofen | Ibuprofen | 270 | 120 |
| Fluticasone Propionate | Fluticasone Propionate | 268 | 90 |
| Jardiance | Empagliflozin | 263 | 47 |
| Montelukast Sodium | Montelukast Sodium | 257 | 62 |
| Allopurinol | Allopurinol | 239 | 70 |
| Vascepa | Icosapent Ethyl | 236 | 54 |
| Glimepiride | Glimepiride | 230 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 217 | 59 |
| Lisinopril | Lisinopril | 209 | 58 |
| Donepezil Hcl | Donepezil Hcl | 204 | 45 |
| Baclofen | Baclofen | 203 | 65 |
| Loperamide | Loperamide Hcl | 203 | 129 |
| Hydrocortisone | Hydrocortisone | 201 | 53 |
| Meclizine Hcl | Meclizine Hcl | 197 | 88 |
| Metformin Hcl Er | Metformin Hcl | 195 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 189 | 63 |
| Diflorasone Diacetate | Diflorasone Diacetate | 171 | 102 |
| Finasteride | Finasteride | 171 | 36 |
| Meloxicam | Meloxicam | 168 | 58 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 167 | 51 |
| Clobetasol Propionate | Clobetasol Propionate | 161 | 49 |
| Pravastatin Sodium | Pravastatin Sodium | 160 | 36 |
| Benazepril Hcl | Benazepril Hcl | 156 | 34 |
| Trazodone Hcl | Trazodone Hcl | 156 | 48 |
| Azithromycin | Azithromycin | 149 | 118 |
| Prednisone | Prednisone | 145 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 135 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 132 | 31 |
| Levothyroxine Sodium | Levothyroxine Sodium | 130 | 29 |
| Furosemide | Furosemide | 124 | 32 |
| Glipizide | Glipizide | 115 | 30 |
| Lansoprazole | Lansoprazole | 115 | 22 |
| Icosapent Ethyl | Icosapent Ethyl | 105 | 35 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 102 | 34 |
| Januvia | Sitagliptin Phosphate | 97 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 96 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 29 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 93 | 23 |
| Cyclosporine | Cyclosporine | 92 | 32 |
| Amoxicillin | Amoxicillin | 90 | 55 |
| Restasis | Cyclosporine | 90 | 18 |
| Ketoconazole | Ketoconazole | 88 | 20 |
| Eliquis | Apixaban | 87 | 15 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 87 | 28 |
| Prolia | Denosumab | 87 | 55 |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 23 |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 84 | 38 |
| Myrbetriq | Mirabegron | 84 | 19 |
| Megestrol Acetate | Megestrol Acetate | 82 | 25 |
| Nifedipine Er | Nifedipine | 82 | 20 |
| Sildenafil Citrate | Sildenafil Citrate | 81 | 16 |
| Clonidine Hcl | Clonidine Hcl | 79 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 79 | 19 |
| Linzess | Linaclotide | 79 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 77 | 62 |
| Rybelsus | Semaglutide | 77 | 15 |
| Colchicine | Colchicine | 73 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 72 | 15 |
| Silver Sulfadiazine | Silver Sulfadiazine | 72 | 19 |
| Dexlansoprazole Dr | Dexlansoprazole | 71 | 16 |
| Procto-Med Hc | Hydrocortisone | 71 | 22 |
| Valsartan | Valsartan | 71 | 16 |
| Naproxen | Naproxen | 68 | 23 |
| Carvedilol | Carvedilol | 63 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 21 |
| Propranolol Hcl | Propranolol Hcl | 61 | 14 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 58 | 18 |
| Ciclopirox | Ciclopirox | 58 | 23 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 57 | 38 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 57 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | 14 |
| Lidocaine | Lidocaine | 54 | 12 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 48 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 48 | 14 |
| Glipizide Er | Glipizide | 46 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 44 | 11 |
| Methotrexate | Methotrexate Sodium | 44 | 13 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 43 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 41 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | 12 |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 40 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 40 | 25 |
| Clotrimazole | Clotrimazole | 39 | 15 |
| Naproxen Sodium | Naproxen Sodium | 39 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 39 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 39 | suppressed |
| Methimazole | Methimazole | 37 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 36 | 13 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 36 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 35 | 13 |
| Calcipotriene | Calcipotriene | 34 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 33 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 33 | suppressed |
| Acyclovir | Acyclovir | 32 | 20 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 31 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 31 | suppressed |
| Creon | Lipase/Protease/Amylase | 30 | suppressed |
| Dutasteride | Dutasteride | 30 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Brilinta | Ticagrelor | 29 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 27 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 27 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 27 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | suppressed |
| Benzonatate | Benzonatate | 24 | 14 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 24 | suppressed |
| Tradjenta | Linagliptin | 24 | suppressed |
| Tacrolimus | Tacrolimus | 23 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 22 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 21 | suppressed |
| Cilostazol | Cilostazol | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 16 |
| Metronidazole | Metronidazole | 19 | 15 |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 19 | suppressed |
| Proctozone-Hc | Hydrocortisone | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Ozempic | Semaglutide | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 17 |
| Tramadol Hcl | Tramadol Hcl | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 15 |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Dexilant | Dexlansoprazole | 15 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 14 | 11 |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Lofena | Diclofenac Potassium | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Xiidra | Lifitegrast | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 13 | suppressed |
| Repaglinide | Repaglinide | 13 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 13 | suppressed |
| Cyclosporine Modified | Cyclosporine, Modified | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | 11 |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Lactated Ringers | Ringer's Solution,lactated | 11 | suppressed |
| Licart | Diclofenac Epolamine | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Tretinoin | Tretinoin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,429.17 · 47 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BENLYSTA, BREZTRI, Bimzelx, COSENTYX, GEMTESA, KRYSTEXXA, Kerendia, NURTEC ODT, OTEZLA, REPATHA, REZDIFFRA, SIMPONI ARIA, TREMFYA, Veozah, ZAVZPRET, ZTLido | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error